Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 6NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 208Carcinoma, Ovarian Epithelial 133Fallopian Tube Neoplasms 117Uterine Cervical Neoplasms 103Breast Neoplasms 76Endometrial Neoplasms 73Pancreatic Neoplasms 33Neoplasms 31Colonic Neoplasms 28Stomach Neoplasms 27Carcinoma, Non-Small-Cell Lung 27Prostatic Neoplasms 26Testicular Neoplasms 24Sarcoma 23Lung Neoplasms 23Melanoma 22Carcinoma, Renal Cell 22Rectal Neoplasms 21Colorectal Neoplasms 20Vaginal Neoplasms 18Uterine Cervical Dysplasia 18Carcinoma, Hepatocellular 18Neoplasm Metastasis 17Anus Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Esophageal Neoplasms 16Brenner Tumor 16Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Vulvar Neoplasms 14

Interventions

amatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Pancreatic Ductal × Gynecologic × Clear all
NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡